When was Theolytics founded?

Theolytics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Theolytics located?

Theolytics is headquartered in Headington, United Kingdom.

Which legal entities is Theolytics associated with?

Theolytics is associated with THEOLYTICS LTD.

How many employees does Theolytics have?

As of Aug 31, 2026, the latest employee count at Theolytics is 29.

Is Theolytics a funded company?

Theolytics is a funded company, having raised a total of $33.6M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 26, 2019.

When was the latest funding round of Theolytics?

Theolytics' latest funding was a $***** Grant (prize money) round on Mar 04, 2026, with participation from 1 investor. Its primary sector is Oncology. In United Kingdom, the Oncology sector has seen $526M in funding in 2026 to date.

Where does Theolytics rank among its competitors?

Theolytics ranks 279th amongst 3393 active competitors, of which 1128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Theolytics?

Theolytics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Theolytics - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of oncolytic adenovirus for the treatment of cancer. The company uses a phenotypic screening platform with viruses, particularly adenoviruses, to develop targeted candidates suitable for intravenous delivery and optimized for specific patient populations.

Website: www.theolytics.com/
Social
Email ID: *****@theolytics.com
Phone Number: +44 **********

Key Metrics

Founded Year

2017

Location

Headington, United Kingdom

Stage

Series B

Total Funding

$33.6M in 6 rounds

Latest Funding Round

Grant (prize money), Mar 04, 2026, $*****

Investors

Epidarex Capital & 12 more

Ranked

279^th among 3393 active competitors

Employee Count

29 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3016 more

View Theolytics' full profile

Theolytics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
THEOLYTICS LTD CIN: 11001290 , United Kingdom, Active	Oct 05, 2017	-	30 (As on Dec 31, 2023)

Theolytics has raised a total funding of $33.6M over 6 rounds. Its first funding round was on Jun 26, 2019. Its latest funding round was a Grant (prize money) round on Mar 04, 2026 for $*****. 1 investor participated in its latest round. Theolytics has 11 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Theolytics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2026	4956048	Grant (prize money)	8041707	8810735	1845205	4267142
Sep 02, 2024	4077643	Grant (prize money)	3165120	5976514	1800047	Ukri
Apr 17, 2024	4265028	Series B	7248445	6907480	Sound Bioventures	M Ventures & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Theolytics's funding rounds and investors

Theolytics' employee count trend

Theolytics has 29 employees as of Aug 26. Here is Theolytics's employee count trend over the years:

Uncover Theolytics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Theolytics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Theolytics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
279th	Theolytics 2017, Headington (United Kingdom), Series B	Developer of oncolytic adenovirus for the treatment of cancer	$33.6M	Oxford Science Enterprises, Epidarex Capital ... & 11 others	57/100